» Articles » PMID: 3148473

Multi-variate Analysis of Factors Governing the Pharmacokinetics of Exogenous Factor VIII in Haemophiliacs

Overview
Specialty Pharmacology
Date 1988 Jan 1
PMID 3148473
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of Factor VIII was evaluated by mathematical modeling in a large-scale study in 62 haemophilia-A subjects, in whom 137 plasma Factor VIII-time curves were measured during single dose (n = 87) and repeated-dose (n = 47) treatments for prophylaxis or minor bleeding episodes. The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h. Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h. In patients with mild haemophilia, pharmaco-statistical analysis revealed that the endogenous synthesis of Factor VIII was constant and was not influenced by the administration of exogenous Factor VIII. The coefficient of variation for intra-individual variability of Factor VIII kinetics (estimated according to the Standard Two-Stage method) was 20.7% in single-dose curves and 23.2% in repeated-dose curves.

Citing Articles

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.

Preijers T, Schutte L, Kruip M, Cnossen M, Leebeek F, Van Hest R Clin Pharmacokinet. 2020; 60(1):1-16.

PMID: 32936401 PMC: 7808974. DOI: 10.1007/s40262-020-00936-5.


Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.

Loomans J, Stokhuijzen E, Peters M, Fijnvandraat K J Clin Transl Res. 2019; 3(Suppl 2):351-357.

PMID: 30873482 PMC: 6412613.


The History of Clotting Factor Concentrates Pharmacokinetics.

Morfini M J Clin Med. 2017; 6(3).

PMID: 28335525 PMC: 5373004. DOI: 10.3390/jcm6030035.


Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Kosloski M, Pisal D, Mager D, Balu-Iyer S J Pharm Sci. 2013; 102(7):2380-94.

PMID: 23620343 PMC: 3676521. DOI: 10.1002/jps.23566.

References
1.
Matucci M, Messori A, Longo G, Vannini S, Morfini M, Tendi E . Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand J Haematol. 1985; 34(1):22-8. DOI: 10.1111/j.1600-0609.1985.tb00739.x. View

2.
Messori A, Longo G, Morfini M, Matucci M, Ruffo S, Tendi E . Individualization of Factor VIII dosage. J Clin Hosp Pharm. 1984; 9(2):95-103. DOI: 10.1111/j.1365-2710.1984.tb01065.x. View

3.
Noe D, Bell W, Ness P, Levin J . Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. Blood. 1986; 67(4):969-72. View

4.
Sheiner L, Beal S . Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983; 11(3):303-19. DOI: 10.1007/BF01061870. View

5.
Whiting B, Kelman A, Grevel J . Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet. 1986; 11(5):387-401. DOI: 10.2165/00003088-198611050-00004. View